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Abstract  
Objective. To develop and validate a risk score [global APS score (GAPSS)] derived from the combination of 
independent risk for thrombosis and pregnancy loss (PL), taking into account the aPL profile, conventional 
cardiovascular risk factors and the autoimmune antibody profile. Methods. This cross-sectional study included 211 
consecutive SLE patients. Data on clinical manifestations, conventional cardiovascular risk factors, aPL profile, ANAs, 
ENA and anti-dsDNA were collected. Long-term low-dose aspirin, oral anticoagulant and HCQ treatment were also 
included in the analysis. Patients were randomly divided into two sets by a computer-generated randomized list. We 
developed GAPSS in the first set of patients (n = 106), assigning the risk factors identified by multivariate analysis 
weighted points proportional to the b-regression coefficient values. GAPSS was validated in the second set of patients 
(n = 105). The relationship between GAPPS and thrombosis and/or PL was analysed. Results. In the first set, higher 
values of GAPSS were seen in patients who experienced thrombosis and/ or PL compared with those without clinical 
events [GAPSS 9.3 (4.8) (range 119) and 5.3 (4) (range 016), P < 0.001]. Also taken separately, patients who 
experienced thrombosis or PL showed higher GAPSS compared with those without clinical events [GAPSS 9.6 (4.8) 
(range 119) vs 4.9 (5) (range 014), P = 0.027 for thrombosis; 7.3 (5) vs 3.9 (5.1) (range 016), P = 0.024 for PL, 
respectively]. In the second set, the results were similar, with statistically higher values of GAPSS in patients with a 
clinical history of thrombosis and/or PL compared with those without events [GAPSS 9.5 (5.6) (range 020) and 3.9 (4.1) 
(range 017), P < 0.001). Higher values were also seen when subclassifying the patients according to the clinical 
manifestation, thrombosis or PL [GAPSS 9.5 (5.6) (range 020) vs 4.8 (5.4) (range 017), P = 0.036 for thrombosis; 7.9 
(3.3) vs 3.8 (5.4) (range 016), P = 0.037 for PL, respectively). Conclusion. These data propose a substantial 
improvement in risk prediction of thrombosis or PL in SLE based on assessment of the GAPSS, a quantitative scoring 
system.  
Key words: antiphospholipid antibodies, pregnancy loss, thrombosis, Hughes syndrome, prothrombin.  
 
Introduction  
APS is defined by the persistent presence of moderate to high serum levels of aPLs in association with thrombotic 
events, pregnancy loss (PL) or both [1]. Several studies have investigated predictors for APS, but it is difficult to draw 
conclusions owing to the substantial differences in study design, patient selection criteria, aPL profiles and the risk 
factors included in the analysis [24]. Recently Otomo et al. [5] developed the aPL score (aPL-S) in an attempt to 
quantify the probability of APS. By testing multiple aPLs, they successfully evaluated its efficacy for the diagnosis of 
APS and its predictive value for thrombosis. Later on, our group independently validated the aPL-S [6]. Although this 
score is a useful quantitative index for diagnosing APS, it does not take into account associated conventional risk 
factors for thrombosis in addition to the aPL profile or evaluate the risk for PL, a common feature of APS. 
We conducted a cross-sectional study in a large cohort of well-characterized SLE patients. Our main objective was to 
develop a risk score [global APS score (GAPSS)] derived from the combination of independent risk for thrombosis and 
PL, taking into account the aPL profile (including criteria and non-criteria aPL), the conventional cardiovascular risk 
factors and the autoimmune antibody profile. The validity of this risk score was then tested in a separate cohort of 
patients. 
 
Patients and methods  
Patients 
This study included 211 consecutive patients who attended the Louise Coote Lupus Unit at St Thomas’ Hospital, 
London. All the patients fulfilled the 1982 criteria for SLE [7]. Data on clinical manifestations, conventional 
cardiovascular risk factors (smoking, hyperlipidaemia, arterial hypertension, oral contraceptive, HRT and diabetes), 
aPL profile, ANA, ENA (including Ro, LA, Sm, RNP) and anti-dsDNA were collected. Long-term lowdose aspirin (100 mg), 
oral anticoagulant and HCQ treatment were also included in the analysis. The aPL profile included aCLs, lupus 
anticoagulant (LA), anti b2-glycoprotein I antibody (anti-b2GPI), antibodies to solid-phase prothrombin (aPT) and to 
phosphatidylserineprothrombin complex (aPS/PT), antibodies to phosphatidylethanolamine (aPE) and antibodies 
directed against protein S (anti-ProtS). aPL testing was considered positive only if confirmed at least 12 weeks apart. 
PL was defined according to current APS classification criteria [1]. Ethical approval was obtained from the Guy’s and St 
Thomas’ Ethics Committee and all patients involved in this study gave their written consent. Demographic, clinical and 
laboratory characteristics are summarized in Table 1. Data were collected on a database and patients were randomly 
divided into two sets. A computer-generated randomized list of patients filtered by the criterion of the diagnosis in 
order to equally distribute the disease prevalence (SLE/APS, SLE/aPL or SLE alone) was generated. To confirm the 
efficacy of randomization, the prevalence of the variables in the two sets was computed and no statistical difference 
was found. The same clinical and laboratory data were available for analysis in both cohorts. These two groups of 
patients are referred to as the development and validation cohort, respectively. 
Assessment of cardiovascular risk factors 
Cardiovascular risk factors were assessed following NICE guidelines [8]. In detail, enrolled patients underwent a 
physical examination, blood pressure determination and phlebotomy for vascular risk factors. Arterial hypertension 
was defined as high blood pressure on at least two occasions or use of oral hypertensive medication. Serum total and 
HDL cholesterol levels were determined with standardized enzymatic methods and interpreted according to current 
cut-off values. Cigarette smoking status was ascertained by self-report. Diabetes was defined as fasting glucose ≥ 126 
mg/dl on at least two occasions or use of insulin or oral hypoglycaemic medication. 
Detection of autoantibodies  
aCL and anti-b2GPI were detected by ELISA as described previously [9, 10]. Plasma samples were tested for the 
presence of LA according to the recommended criteria of the ISTH Subcommittee on Lupus Anticoagulant/ 
Antiphospholipid-dependent antibodies [11]. Antibodies to prothrombin were tested by the aPT and aPS-PT as 
previously reported [12, 13]. aPE and antiProtS were tested as described elsewhere [14, 15]. ANA was measured by IIF 
on rodent liver cells, anti-dsDNA antibodies by RIA (Farr assay) and antibodies to ENA by CIE using bovine spleen and 
rabbit thymus extracts. 
Statistical analysis  
Categorical variables are presented as numbers and percentages, and continuous variables are presented as means 
(S.D.). The significance of baseline differences was determined by the chi-square test, Fisher’s exact test or the 
unpaired t-test, as appropriate. A two-sided P < 0.05 was considered statistically significant. Univariate and 
multivariate logistic regression analyses were used to determine the contribution of the variables in the first cohort of 
SLE patients, referred to as the development cohort. A step-wise forward conditional procedure was used for the 
multivariate logistic regression analysis, including all the significant risk factors obtained by the univariate analysis. To 
develop the GAPSS, we assigned the risk factors identified by multivariate analysis weighted points proportional to the 
b-regression coefficient values (rounded to the nearest integer). In detail, assignment of points to risk factors was 
based on a linear transformation of the corresponding b-regression coefficient. The coefficient of each variable was 
divided by 0.54 (the lowest b-value, corresponding in our cohort to arterial hypertension) and rounded to the nearest 
integer. The formula used can be summarized as follows: GAPPS point = [bx/bmin], where bx is the b-regression 
coefficient for the variable x taken into account and bmin is the lowest b-value among the significant variables after 
multivariate analysis. For example, in our cohort, the GAPPS score for hyperlipidaemia is 3 as the GAPPS point = 
[bhyperlipidaemia/barterial hypertension] = [1.73/0.54] = [3.20] = 3, rounded to the nearest integer. A risk score was 
then calculated for each patient in both development and validation cohorts. Sensitivity, specificity and positive and 
negative predictive values (PPV and NPV, respectively) were calculated to compare the accuracy between the 
different possible cut-off values for GAPSS. Areas under the receiver operating characteristic curve (AUC) of different 
cut-off values were computed. All statistical analyses were performed using SPSS 19.0 (SPSS, Chicago, IL, USA). 
Results  
Development color 
The development cohort comprised 106 SLE patients with a mean (S.D.) age of 42.6 (12.1) years and mean disease 
duration of 13.4 (8.8) years. Overall, 44 patients fulfilled the criteria for APS [1] and 36 patients had a history of 
thrombosis (23 arterial, 23 venous thrombosis). Out of 75 women who had ever been pregnant, 23 had a history of 
miscarriages and 16 a history of fetal death. Demographics are summarized in Table 1. 
Validation cohort  
The validation cohort comprised 105 SLE patients with a mean (S.D.) age of 42.8 (12.0) years and mean disease 
duration of 11.4 (9.1) years. Of them, 37 patients had a history of thrombosis (25 arterial, 18 venous thrombosis). Out 
of 69 women who had ever been pregnant, 18 had a history of miscarriage and 18 had a history of fetal death. 
Demographics are summarized in Table 1. 
Analysis of risk factors for thrombosis and PL  
Univariate and multivariate models analysed all clinical and laboratory characteristics in the development cohort, 
including thrombosis risk factors, as indicated in Tables 2 and 3. Odds ratio analysis reported that among conventional 
cardiovascular risk factors, arterial hypertension and hyperlipidaemia had an association with thrombosis and/or PL (P 
= 0.035 and P = 0.036, respectively). Anti-ENA and anti-RNP positivity were associated with thrombosis and/or PL (P = 
0.039 and P = 0.047, respectively). For aPL, LA, aCL IgG and/or IgM, anti-b2GPI IgG and/or IgM, aPT IgG and/or IgM, 
and aPS/PT IgG and/or IgM showed an association with thrombosis and/or PL (P = 0.031, P = 0.023, P = 0.049, P = 
0.034 and P = 0.006, respectively). Multivariate logistic regression analysis showed that only arterial hypertension, 
hyperlipidaemia, LA, aCL IgG and/or IgM, anti-b2GPI IgG and/or IgM and aPS/PT IgG and/or IgM were independent risk 
factors for thrombosis and/or PL (Table 3). 
Development and validation of GAPSS  
To calculate GAPSS, we assigned each of the six variables identified in the development cohort as independent risk 
factors for thrombosis and/or PL, a number of points that was proportional to its regression coefficient, as previously 
described. A score was calculated for each patient by adding together the points corresponding to the risk factors. In 
the development cohort, higher values of GAPSS were seen in patients who experienced thrombosis and/or PL 
compared with those without clinical events [GAPSS 9.3 (4.8) (range 119) and 5.3 (4) (range 016), P < 0.001]. Also 
taken separately, patients who experienced thrombosis or PL showed higher GAPSS compared with those without 
clinical events [GAPSS 9.6 (4.8) (range 119) and 4.9 (5.0) (range 014), P = 0.027 for thrombosis; 7.3 (5) and 3.9 (5.1) 
(range 016), P = 0.024 for PL, respectively]. In the validation cohort the results were similar, with statistically higher 
values of GAPSS in patients with a clinical history of thrombosis and/or PL compared with those without events 
[GAPSS 9.5 (5.6) (range 020) and 3.9 (4.1) (range 017), P < 0.001] (Fig. 1A). Higher values were also seen when 
subclassifying the patients according to the clinical manifestation, thrombosis or PL [GAPSS 9.5 (5.6) (range 020) and 
4.8 (5.4) (range 017), P = 0.036 for thrombosis; 7.9 (3.3) and 3.8 (5.4) (range 016), P = 0.037 for PL, respectively] (Fig. 
1B). The diagnostic accuracy for different cut-off values was also assessed. Sensitivity, specificity, PPV and NPV are 
shown in Table 4. The computed AUC demonstrated that GAPSS values 510 had the best diagnostic accuracy 
compared with the different thresholds (Fig. 2).  
 
Discussion 
APS is a heterogeneous entity with wide variation in clinical course and laboratory profile. In this study, six variables 
including arterial hypertension, hyperlipidaemia, aCL, LA, anti-b2GPI and aPS/PT were shown to be independent risk 
factors for thrombosis and PL after multivariate analysis. A score derived by combining points for each of these six 
features was set up in a development color and validated in a separate cohort of patients. In this pilot study, we 
report that higher levels of GAPSS correlate with the major features of APS in a large cohort of SLE patients, suggesting 
that this score could be used as a potential quantitative marker for APS. In 2011 we set up a preliminary risk model 
taking into account the issue of aPL profiles in the assessment of the risk for clinical events in APS [16]. More recently, 
Otomo et al. [5] elaborated an aPL-S with the purpose of quantifying the risk based on the aPL profile. An algorithm 
was created based on multiple aPL assays, with each assay being assigned a different score weighted on the relative 
risk of having clinical manifestations of APS as calculated in a cohort of patients affected by systemic autoimmune 
diseases. The strength of our GAPSS, when compared with the previous proposed score, includes several points, one 
of the most relevant being the inclusion of conventional cardiovascular risk factors in the setting up of our model. 
Many observational studies have demonstrated the role of concomitant vascular risk factors such as hypertension, 
hypercholesterolaemia, smoking or oestrogen therapy in the development of thrombosis. Our data support the 
multifactorial nature of thrombosis and PL, as a higher incidence of arterial hypertension and hyperlipidaemia was 
found in patients with higher GAPSS score [17]. Moreover, our study included a very homogeneous cohort of 211 
patients from a single centre, all classified as having SLE by strict fulfilment of criteria. In addition to the ongoing 
debate about the value of multiple aPL positivity [18], our study evaluated the aPL profile of patients taking into 
account criteria and non-criteria aPL [19, 20]. To the best our knowledge, this is the first score evaluating a panel of 
seven different aPLs, all shown to be relevant in APS [2124]. In the current study, patients with higher GAPSS had a 
higher prevalence of multiple aPL positivity, whereas single or dual positivity was seen in patients with lower GAPSS. 
Our data support the notion that a combination of aPL tests should be considered when discussing the risk of 
thrombosis and/or pregnancy morbidity. It is also true that our model has some limitations. First, a limitation of our 
analysis is the use of a history of thrombosis and/or PL rather than actual events as outcome. This use of a proxy 
outcome measure (inevitable in a cross-sectional study) may lead to misclassification in either direction, although the 
efficacy of this approach for cardiovascular risk factor evaluation has been demonstrated in diverse populations 
[2527]. We also used dichotomized variables. Although this strategy simplified the creation of the risk score, making it 
more widely adoptable, the use of continuous variables would have the potential to provide more refined 
information. This is work in progress. In addition, we acknowledge that no consensual standardized method exists for 
the detection of non-criteria aPL, currently limiting the clinical application of these tests in routine practice. In this 
study we could not assess the effect of therapy because treatment was not controlled, but varied according to the 
clinical manifestations. Furthermore, these findings should also be validated in a prospective fashion, including not 
only primary APS but also aPL-positive patients without clinical symptoms suggestive of APS or other autoimmune 
disease. In summary, we developed the GAPSS as a score model based on six clinical factors that has been proved to 
represent the probability or likelihood of having thrombosis or PL in SLE. This score was validated in a statistically 
independent sample of patients. The use of GAPSS may provide important information regarding thrombosis or PL risk 
for each SLE patient, switching from the concept of aPL as diagnostic antibodies to aPL as risk factors for clinical 
events. These data propose a substantial improvement in risk prediction of thrombosis or PL in SLE based on 
assessment of the GAPSS, a quantitative scoring system. In turn, such an approach on the categorization of SLE 
patients based upon different combinations of positive aPL tests and conventional cardiovascular risk factors may, in 
future, influence not only prognostic judgement but also, more critically, pharmacological treatment. In conclusion, 
we demonstrated that the risk profile in APS can be successfully assessed by GAPSS, suggesting that GAPSS can be a 
potential quantitative marker of APS. Clearly these observations need to be validated in prospective studies. 
 
Rheumatology key messages  
. GAPSS is based upon combinations of positive aPL tests and conventional cardiovascular risk factors.  
. A combination of aPL tests should be considered when assessing the risk of thrombosis/PL in SLE.  
. GAPSS represents an improvement in assessment of the risk of thrombosis/PL in SLE patients. 
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TABLE 1 
Demographic and clinical characteristics of the development and validation cohorts 
 
 
 
 
 
 
 
 
LDA: low-dose aspirin; OA: oral anti-coagulation. 
 
 
 
 
 
 
 
 
 
 
TABLE 2 Univariate logistic regression analysis for the development cohort 
 
 
OR (95% CI) P 
Conventional risk factors (≥1) 1.84 (0.782, 4.253) 0.19 
Smoking     0.823 (0.353, 1.920) 0.08 
Oral contraceptive pill     0.558 (0.160, 1.950) 0.21 
Hyperlipidaemia     2.492 (1.28, 5.918) 0.036 
Arterial hypertension     1.831 (1.099, 8.280) 0.035 
Diabetes     1.831 (0.81, 21.938) 0.6 
HRT     3.55 (0.655, 13.23) 0.15 
Anti-dsDNA 1.63 (0.738, 3.59) 0.53 
ENA 1.304 (1.127, 2.780) 0.039 
Anti-RO/SSA     0.471 (0.188, 9.178) 0.31 
Anti-LA/SSB     1.885 (0.315, 7.482) 0.27 
Anti-RNP     1.324 (1.116, 6.09) 0.047 
Anti-Sm     0.369 (0.124, 2.0979) 0.61 
aCL IgG/IgM 3.998 (1.987, 10.448) 0.023 
Anti-β2GPI IgG/IgM 3.98 (1.462, 10.892) 0.049 
aPT IgG/IgM 2.778 (1.037, 7.47) 0.034 
aPS/PT IgG/IgM 2.133 (1.368, 7.128) 0.006 
aProtS IgG 1.424 (0.177, 8.22) 0.19 
aPE IgG/IgM 1.997 (0.457, 2.193) 0.22 
LA 1.885 (1.116, 8.507) 0.031 
LDA 0.379 (0.141, 3.193) 0.47 
HCQ 0.63 (0.438, 3.98) 0.32 
OA 0.55 (0.122, 1.71) 0.67 
 
LDA: low-dose aspirin; OA: oral anti-coagulation; NS: non-significant. 
 
 
 
TABLE 3 Multivariate logistic regression analysis for the development cohort and scoring system 
 
 
 
 
 
β-coefficient GAPSSa 
 Hyperlipidaemia 1.73 3 
 Arterial hypertension 0.54 1 
 aCL IgG/IgM 2.63 5 
 Anti-β2GPI IgG/IgM 2.02 4 
 aPS/PT IgG/IgM 1.78 3 
 LA 2.35 4 
 
 
aAssignment of points to risk factors was based on a linear transformation of the corresponding β-regression 
coefficient by using the formula GAPSS = [βx/βmin], where βx is the β-regression coefficient for the variable x and 
βmin is the lowest β-value among the significant variables in the whole population after multivariate analysis. For 
example, in this cohort, the GAPSS for hyperlipidaemia is 3, as GAPSS = [βhyperlipidaemia/βarterial hypertension] = 
[1.73/0.54] = 3.20 = 3, when rounded to the nearest integer. 
 
 
 
 
FIG. 1 GAPSS in development and validation cohorts. 
 
(A) Distribution of GAPSS in SLE in the development and validation cohorts. Data are shown as box plots, where 
each box represents the 25th–75th percentiles: lines inside the box represent the median. The whiskers 
represent the 95% CI. Higher values of GAPSS were seen in patients who experienced thrombosis and/or PL 
when compared with those without clinical events in both development and validation cohorts. (B) 
Distribution of GAPSS in SLE in the development and validation cohorts, analysing separately patients who 
experienced thrombosis or PL. Data are shown as box plots, where each box represents the 25th–75th 
percentiles: lines inside the box represent the median. The whiskers represent the 95% CI. Higher values of 
GAPSS were seen in patients who experienced thrombosis or PL when compared with those without clinical 
events in both development and validation cohorts. 
 
  
 
 
 
FIG. 2 Receiver operating characteristic curves computed using different GAPSS thresholds. The AUC was calculated 
according to the presence of a history of thrombosis and/or PL. 
 
 
 
 
 
TABLE 4 
Diagnostic accuracy including sensitivity, specificity, PPV and NPV for different cut-off values of GAPSS 
 
 
                                               AUC Sensitivity     Specificity NPV PPV P-value 
GAPSS cut off = 10 0.736 0.709       0.793 0.7705 0.7045 0.000 
GAPSS cut off = 12 0.697 0.578       0.817 0.7206 0.7027 0.001 
GAPSS cut off = 15 0.664 0.378       0.950               0.6706 0.8500 0.004 
